Matrix degradation in renal disease

Nephrology

Volumn 2, Issue 1, 1996, Pages 13-23

  Jones, Colin L ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Matrix metalloproteinases; Plasminogen activator; Renal fibrosis; Tissue inhibitor of matrix metalloproteinase; Tissue remodelling

Indexed keywords

EID: 0001810917     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1996.tb00061.x     Document Type: Review

References (97)

1. Jones CL, Eddy AA. Tubulointerstitial nephritis. Pediatr. Nephrol. 1992; 6: 572-86.
2. Schainuck LI, Striker GE, Cutler RE, Benditt EP. Structural-functional correlations in renal disease. II. The correlations. Hum. Pathol. 1970; 1: 631-41.
3. Gonzalez-Avila G, Vadillo-Ortega F, Perez-Tamayo R. Experimental diffuse interstitial renal fibrosis: A biochemical approach. Lab. Invest. 1988; 59: 245-52.
4. Haralambous-Gasser A, Chan D, Walker RG, Powell HR, Becker GJ, Jones CL. Collagen studies in newborn rat kidneys with incomplete ureteric obstruction. Kidney Int. 1993; 44: 593-605.
5. Eddy AA. Protein restriction reduces transforming growth factor-β and interstitial fibrosis in nephroric syndrome. Am. J. Physiol. 1994; 266: F884-93.
6. Freije JMP, Diez-Itza I, Balbin M et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 1994; 269: 16766-73.
7. Gay S, Miller EJ. Collagen in the Physiology ana Pathology of Connective Tissue. Gustav Fischer Verlag, Stuttgart 1978; 24-35.
8. Nagase H. Matrix metalloproteinases: A mini-review. Contrib. Nephrol. 1994; 107: 85-93.
9. Overall CM, Sodek J. Concanavalin-A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72 kDa gelatinase, and PUMP-1 is accompanied by suppression of the tissue inhibitor of matrix metalloproteinases. J. Biol. Chem. 1990; 265: 21141-51.
10. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinases 3 (stromelysin) activates the precursor for the human matrix metalloproteinases 9. J. Biol. Chem. 1992; 267: 3581-4.
11. Van Wart HE, Birkedal-Hansen H. The cysteine switch: A principle of regulation of metalloproteinase gene family. Proc. Natl Acad. Sci. USA 1990; 87: 5578-82.
12. Alexander CM, Werb Z. Proteinases and extracellular matrix remodeling. Curr. Opin. Cell Biol. 1989; 1: 974-82.
13. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990; 6: 121-5.
14. Frisch SM, Clark EJ, Werb Z. Coordinate regulation of stromelysin and collagenase genes determined with cDNA probes. Biochemistry 1987; 84: 2600-4.
15. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Disco-ordinate expression of stromelysin, collagenase and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-α on stromelysin expression. J. Biol. Chem. 1990; 265: 17238-45.
16. Unemori EN, Bair MJ, Bauer EA, Amento EP. Stromelysin expression regulates collagenase activation in human fibroblasts. Dissociable control of two metalloproteinases by interferon-γ. J. Biol. Chem. 1991; 266: 23477-82.
17. He C, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI. Tissue cooperation is a proteolytic cascade activating human interstitial collagenase. Proc. Natl Acad. Sci. USA 1989; 86: 2632-6.
18. Docherty AJF, Lyons A, Smith BJ et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985; 318: 66.
19. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-1): A new member of the metalloproteinase inhibitor family. J. Biol. Chem. 1989; 264: 17374-8.
20. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991; 5: 2145-54.
21. Leco KJ, Khokha R, Pavioff N, Hawkes S, Edwards DR. Tissue inhibitor of metalloproteinase-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J. Biol. Chem. 1994; 269: 9352-60.
22. Yang TT, Hawkes SP. Role of the 21 kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc. Natl Acad. Sci. USA 1992; 81: 10676-80.
23. Engelmyer E, Van Goor H, Edwards DR, Diamond JR. Differential mRNA expression of renal cortical tissue inhibitor of metalloproteinase-1, -2, and -3 in experimental hydronephrosis. J. Am. Soc. Nephrol. 1995; 5: 1675-83.
24. Murphy G, Houhrechts A, Cockett MI, Williamson RA, O'Shea M, Docherty AJP. The N-tertninal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991; 30: 33.
25. Willenbrock F, Crabbe T, Slocombe PM et al. The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: A kinetic analysis of the inhibition of gelatinase A. Biochemistry 1993; 32: 4330-7.
26. Shapiro SD, Doyle GAR, Ley TJ, Parks WC, Welgus HG. Molecular mechanisms regulating the production of collagenase and TIMP in U937 cells: Evidence for involvement of delayed transcriptional activation and enhanced mRNA stability. Biochemistry 1993; 32: 4286-92.
27. Miyazaki M, Koji T, Furusu A et al. In situ hybridization studies of stromelysin and tissue inhibitor of metalloproteinase 1 in IgA nephropathy. Nephrology 1995; 1: 119-28.
28. Jones CL, Fecondo J, Kelynack K, Forbes J, Walker R, Becker G. Tissue inhibitor of the metalloproteinases and renal extracellular matrix accumulation. Exp. Nephrol. 1995; 3: 80-6.
29. Carome MA, Striker LJ, Peten EP et al. Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA. Am. J. Physiol. 1993; 264: 923-9.
30. Schnaper HW, Grant DS, Stetler-Stevenson WG et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J. Cell. Physiol. 1993; 156: 235-46.
31. Nomura S, Hogan BLM, Wills AJ, Heath JK, Edwards DR. Developmental expression if tissue inhibitor of metalloproteinase (TIMP) RNA. Development 1989; 105: 575-84.
32. Khokha R, Waterhouse P, Yagel S et al. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 1989; 243: 947-50.
33. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range ot cells. A possible new growth factor in serum. FEBS Lett. 1992; 298: 29-32.
34. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem. 1986; 261: 3486-9.
35. Ichinose A, Kisiel W, Fujikawa K. Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes. FEBS Lett. 1984; 175: 412-18.
36. Gaussem P, Grailhe P, Aglés-Cano E. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor. J. Biol. Chem. 1993; 268: 12150-5.
37. Pollanen J, Hedman K, Nielsen IS, Dano K, Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J. Cell. Biol. 1988; 106: 87-95.
38. Schnaper HW, Mazar A, Bamathan ES, Kleinman HK. Urokinase-type plasminogen activator (uPA) enhances endothelial cell differentiation through a non-proteolytic mechanism involving uPA receptor (uPAR) binding. Pediatr. Res. 1994; 35: 373A.
39. Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J. Clin. Invest. 1993; 91: 1541-52.
40. Johnson R, Yamabe H, Chen YP et al. Glomerular epithelial cells secrete a glomerular basement membrane-degrading metalloproteinase. J. Am. Soc. Nephrol. 1992; 2: 1388-97.
41. Liotta LA, Goldfarb RH, Terranova VP. Cleavage of laminin by thrombin and plasmin: Alpha thrombin selectively cleaves the beta chain of laminin. Thromb. Res. 1981; 21: 663-73.
42. Kristensen P, Eriksen J, Dano K. Localisation of urokinase-type plasminogen activator messenger RNA in the normal mse by in situ hybridisation. J. Histochem. Cytochem. 1991; 39: 341-9.
43. Larsson L-I, Skriver L, Nielsen LS, Grondahl-Hansen J, Kristensen P, Dano K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J. Cell. Biol. 1984; 98: 894-903.
44. Angles-Cano E, Rondeau E, Delarue F, Hagege J, Sultan Y, Sraer JD. Identification and cellular localization of plasminogen activators from human glomeruli. Thromb. Haemost. 1985; 54: 688-92.
45. Bergstein JM, Riley M, Bank NU. Analysis of the plasminogen activator of the human glomerulus. Kidney Int. 1988; 33: 868-74.
46. Rondeau E, Ochi S, Locave R. Urokinase synthesis and binding by glomerular epithelial cells in cluture. Kidney Int. 1989; 36: 593-600.
47. Brown PAJ, Wilson HM, Reid FJ et al. Urokinase-plasminogen activator is synthesized in vitro by human glomerular epithelial cells but not by mesangial cells. Kidney Int. 1994; 45: 43-7.
48. Reid FJ, Wilson HM, Moore NR, Power DA, Haites NE. Cultured human mesangial cells produce urokinase (u-PA ) and plasminogen activator inhibitor-1 (PAI-I). (abstract) Fibrinolysis 1992; 6 (Suppl 2): 173.
49. Colucci M, Gesualdo L, Semeraro N et al. The fibrinolytic profile of human mesangial cells (HMC) in culture (Abstract). J. Am. Soc. Nephrol. 1992; 3: 100.
50. Bancos WH, Cortez SL, El-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 1995; 47: 1039-47.
51. Rondeau E, Mougenot B, Lacave R, Peraldi MN, Kruithof EKO, Sraer J-D. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. Clin. Nephrol. 1990; 33: 55-60.
52. Aya N, Yoshioka K, Murakami K et al. Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis. J. Pathol. 1992; 166: 289-95.
53. Aya N, Yoshioka K, Murakami K et al. Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis. J. Pathol. 1992; 166: 289-95.
54. Rondeau E, Mougenot B, Lacave R, Peraldi MN, Kruithof EKO, Sraer JD. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. Clin. Nephrol. 1990; 33: 55-60.
55. Yamaguchi T, Kido H, Kitazawa R, Kitazawa S, Fukase M, Katunuma N. A membrane-bound metallo-endopeptidase from rat kidney: Its immunological characterization. J. Biochem. 1993; 113: 299-303.
56. Marchand P, Tang J, Bond JS. Membrane association and oligomeric organization of the alpha and beta subunits of mouse meprin A. J. Biol. Chem. 1994; 269: 15388-93.
57. Kaushal GP, Walker PD, Shah SV. An old enzyme with a new function: Purification and characterization of a distinct matrix-degrading metalloproteinase in rat kidney cortex and its identification as meprin. J. Cell Biol. 1994; 126: 1319-27.
58. Yamaguchi T, Fukase M, Kido H, Sugimoto T, Katunuma N, Chihara K. Meprin is predominantly involved in parathyroid hormone degradation by the microvillar membranes of rat kidney. Life Sci. 1994; 54: 381-6.
59. Flannery AV, Dalzell GN, Beynon RJ. Proteolytic activity in mouse urine: Relationship to the kidney metallo-endopeptidase, meprin. Biochim. Biophys. Acta 1990; 1041: 64-70.
60. Walker PD, Kaushal GP, Shah SV. Meprin A the major matrix degrading enzyme in renal tubules, produces a novel nidogen fragment. J. Am. Soc. Nephrol. 1994; 5: 912 (Abstract).
61. Trachtman H, Greenwald R, Moak S, Tang J, Bond JS. Meprin activity in rats with experimental renal disease. Life Sci. 1993; 53: 1339-44.
62. Le Q, Shah S, Nguyen H, Correz S, Baricos N. A novel metalloproteinase present in freshly isolated rat glomeruli. Am. J. Physiol. 1991; 260: F555-61.
63. Baricos WH, Cortex SL, Le QC et al. Glomerular basement membrane degradation by endogenous cystein proteinases in isolated rat glomeruli. Kidney Int. 1990; 38: 395-401.
64. Baricos WH, O'Connor SE, Cortz SL, Wu LT, Shah SV. The cysteine proteinase inhibitor, E-64, reduces proteinuria in an experimental model of glomerulonephritis. Biochem. Biophys. Res. Commun. 1988; 155: 1318-23.
65. Baricos WH, Shah SV. Role of cathepsin B and L in anti-glomerular basement membrane nephritis in rats. Renal Physiol. Biochem. 1989; 12: 400-5.
66. 3H] proline. Biochem. J. 1982; 206: 535-44.
67. Schaefer L, Teschner M, Ling H, Oldakowska U, Heidland A, Schaefer RM. The aging rat kidney displays low glomerular and tubular proteinase activities. Am. J. Kidney Dis. 1994; 24: 499-504.
68. Kappel B, Olsen S. Cortical interstitial tissue and sclerosed glomeruli in the normal human kidney, related to age and sex. Virchows Arch. A. Pathol. Anal. Histopathol. 1980; 387: 271-7.
69. Bolton WK, Sturgill BC. Spontaneous glomerular sclerosis in aging Sprague-Dawley rats. Am. J. Pathol. 1980; 98: 339-56.
70. Millis AJ, Hoyle M, McCue HM, Martini H. Differential expression of metalloproteinase and tissue inhibitor of metalloproteinase genes in aged human fibroblasts. Exp. Cell Res. 1992; 201: 373-9.
71. West MD, Pereira-Smith OM, Smith JR. Replicative senescence of human skin fibroblasrs correlates with a loss of regulation and over-expression of collagenase activity. Exp. Cell Res. 1989; 184: 138-47.
72. Fini ME, Girard MT. The pattern of metalloproteinase expression by comeal fibroblasts is altered by passage in cell culture. J. Cell. Sci. 1990; 97: 373-83.
73. Schnaper HW. Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr. Nephrol. 1995; 9: 104-11.
74. Alexander JP, Bradley JMB, Gaboure JD, Acott TS. Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 1990; 31: 2520-8.
75. Lefebvre V, Peeters-Joris C, Vaes G. Production of gelatin-degrading matrix metalloproteinases ('type IV collagenases') and inhibitors by articular chondrocytes during their dedifferentiation by serial subcultures and under stimulation by interleukin-1 and tumor necrosis factor a. Biochem. Biophys. Acta 1991; 1094: 8-18.
76. Reckelhoff JF, Baylis C. Glomerular meralloprotease activity in the aging rat kidney: Inverse correlation with injury. J. Am. Soc. Nephrol. 1993; 3: 1835-8.
77. Carome MA, Striker LJ, Peten EP et al. Assessment of 72-kilodalton gelatinase and TIMP-1 gene expression in normal and sclerotic murine glomeruli. J. Am. Soc. Nephrol. 1994; 5: 1391-9.
78. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H. Effects of methylprednisolone on glomerular and medullary mRNA levels for extracellular matrices in puromycin aminonucleoside nephrosis. Kidney Int. 1991; 40: 874-81.
79. Fukui M, Nakamura T, Ebihara I, Osada S, Tomino Y, Koide H. Diet protein restriction reduces increased mRNA levels encoding for extracellular matrix (ECM) components, metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) in glomeruli from focal glomerulosclerosis (FGS) (Abstract). J. Am Soc. Nephrol. 1992; 3: 630.
80. Nakamura T, Fukui M, Ebihara I, Tomino Y, Koide H. Low protein diet blunts the rise in glomerular gene expression in focal sclerosis. Kidney Int. 1994; 45: 1593-605.
81. Reckelhoff JF, Tygart VL, Racusen LC, Dzielak DJ. Glomerular metalloproteinase activity in streptozotocin-treated rats and in spontaneously diabetic rats (BB/DP). Life Sci. 1994; 55: 941-50.
82. Reckelhoff JF, Tygart VL, Mltias MM, Walcott JL. STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloproteinase in rats. Diabetes 1993; 42: 1425-32.
83. Kitamura M, Kitamura A, Mitarai T et al. Gene expression of metalloproteinase and its inhibitor in mesangial cells exposed to high glucose. Biochem. Biophys. Res. Commun. 1992; 185: 1048-54.
84. Feng L, Tang WW, Loskutoff DJ, Wilson CB. Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibodyglomerulonephritis. J. Am. Soc. Nephrol. 1993; 3: 1753-64.
85. Malliaros J, Holdsworth SR, Wojta J, Erlich J, Tipping PG. Glomerular fibrinolytic activity in anti-GBM glomerulonephritis in rabbits. Kidney Int. 1993; 44: 557-64.
86. Loskutoff DJ, Sawdey M, Keeton M, Schneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb. Haemost. 1993; 70: 135-7.
87. Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. 1992; 42: 1462-9.
88. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990; 346: 371-4.
89. Border WA, Noble NA, Yamamoto T et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360: 361-4.
90. Border WA, Ruoslahti E. Transforming growth factor-β in disease: The dark side of tissue repair. J. Clin. Invest. 1992; 90: 1-7.
91. Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy A. Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am. J. Pathol. 1992; 141: 1381-96.
92. Jones CJ, Buch S, Post M, McCulloch L, Liu E, Eddy A. Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis. Kidney Int. 1991; 40: 1020-31.
93. Overall CM, Wrana JL, Sodek J. Independent regulation of collagenase, 72 kDa progelatinase and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor β. J. Biol. Chem. 1989; 264: 1860-9.
94. Sharma AK, Mauer SM, Kim Y, Michael AF. Interstitial fibrosis in obstructive nephropathy. Kidney Int. 1993; 44: 774-88.
95. Eddy AA. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein overload proteinuria. J. Am. Soc. Nephrol. 1994; 5: 804(A).
96. Eddy AA. Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolaemia. J. Am. Soc. Nephrol. 1994; 5: 804(A).
97. Tang WW, Feng L, Yiyang X, Wilson CB. Extracellular matrix accumulation in immune-mediated tubulointerstitial injury. Kidney Int. 1984; 45: 1077-84.